Targets › PRKCE
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout May 2031.
Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that plays essential roles in the regulation of multiple cellular processes linked to cytoskeletal proteins, such as cell adhesion, motility, migration and cell cycle, functions in neuron growth and ion channel regulation, and is involved in immune response, cancer cell invasion and regulation of apoptosis. Mediates…. (UniProt, Q02156)
Open in Phaseline: the race on PRKCE, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| VM Discovery | VMD-102 PKC epsilon (PKCε) kinase inhibitor | PRKCE | Phase 1 | Hepatocellular Carcinoma (HCC) | May 2031 |
Hepatocellular Carcinoma (HCC) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.